• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Dr. David Healy

Psychiatrist. Psychopharmacologist. Scientist. Author.

  • About
  • Blog
  • Articles
  • Books
  • Cause & Effect
  • Politics of Care
  • Resources

Blog

Trade Wars we have known and loved: Indianapolis v The World

September 10, 2013 Leave a Comment

Several weeks ago Canadians woke up to a Globe and Mail article saying that the pharmaceutical company Eli Lilly, who are based in Indianapolis, was suing their Government for $500 million for loss of revenues linked to the loss of patents on two of its drugs - Zyprexa and Strattera. "The drug giant alleges that the loss of its patents violates Canada’s obligations under … [Read more...] about Trade Wars we have known and loved: Indianapolis v The World

Trade Wars we have known and loved: AbbVie v China

September 5, 2013 7 Comments

Editorial Note: This post is taken from a more complete article published in BMJ today authored by Nigel Hawkes. It tells of a recent European meeting on access to clinical trial data. The meeting had input from AbbVie who it seems shocked everyone in the room shocked with their disregard for patient safety. The details here make it very clear why we need to petition AbbVie … [Read more...] about Trade Wars we have known and loved: AbbVie v China

AbbVie Petition: Drug Hazards are not Trade Secrets

August 30, 2013 5 Comments

dangerous side effects should not be commercial secrets

RxISK has started a petition on Change.org which will go to Richard Gonzalez CEO of AbbVie, and Daniel Welch CEO of InterMune, who are at present taking a legal action to block the European Medicines Agency's policy of open access to clinical trial data. The reason to petition is in this post Let's do the AbbVie again and the Petition is Here. Can you take 30 seconds to … [Read more...] about AbbVie Petition: Drug Hazards are not Trade Secrets

Humira & Hope – and Despair: Annette’s Story

August 30, 2013 2 Comments

Humira

Editorial Note: Many people have wonderful responses to Humira and other biologic drugs like Enbrel (Phil Mickelson in the case of Enbrel). Rheumatoid Arthritis, Crohn's Disease and the other conditions these drugs were first used for are debilitating disorders that need a potent treatment. But if a drug is potent it will have the capacity to cause significant harms. Lots of … [Read more...] about Humira & Hope – and Despair: Annette’s Story

The Humira Trials: Judith’s Story

August 28, 2013 4 Comments

Blister pack containing question marks

Editorial Note: AbbVie's current legal action against the European Medicines Agency's policy on access to clinical trial data led to the idea of an AbbVie - getting people on any drugs at all, especially new drugs and in particular biologicals, to do two things: 1. Report any of the effects they are having on RxISK.org 2. Sign the petition below AbbVie applied to block … [Read more...] about The Humira Trials: Judith’s Story

Stacy London: What Not To Take

August 20, 2013 20 Comments

Humira

Three weeks ago Johanna Ryan and Kim Witczak wrote a letter to Stacy London about Humira and AbbVie. They were hoping for a response but there has been none so far. There’s something about Stacy Stacy London of What Not to Wear fame has a lot going for her. She is a successful business woman, style guru and role model for women around the world. AbbVie must be delighted to … [Read more...] about Stacy London: What Not To Take

Welcome to the Humiraverse

August 15, 2013 9 Comments

Editorial Note: This post in the AbbVie series is by Johanna Ryan from the RxISK Community Advisory Board I recently read a legal complaint filed against AbbVie by a New York woman named Cynthia Di Bartolo. She’s a successful corporate lawyer who had undergone various treatments for psoriasis over the years, including medications and ultraviolet light therapy. In November 2008 … [Read more...] about Welcome to the Humiraverse

Democracy in Adversity

August 9, 2013 7 Comments

Pharma emerging markets

This post stands in stark contrast to EU-nuch in the Humira-m. There could not be a greater contrast between the way companies now sell drugs globally and the way they attempt to restrict the reporting of adverse events. The infographic below from Kayla brings out the point. Sales are now global. AbbVie's plans for Humira and the plans other companies have for their … [Read more...] about Democracy in Adversity

EU-nuch in the Humira-m

August 7, 2013 3 Comments

No such thing as being 'European' There is no such thing as being European when you take a drug like Humira or Depakote and something goes wrong. When something goes wrong on their drug, companies go to extraordinary lengths to make it almost impossible for doctors or patients to report adverse events. It’s part of a larger mission to transform what were poisons to be used … [Read more...] about EU-nuch in the Humira-m

Humira in Ulcerative Colitis

July 29, 2013 60 Comments

Editorial Note: I have to thank Ken Spriggs for pointing out the Humira in Ulcerative Colitis Review site. For anyone interested in AbbVie-ing and in Humira this site offers some sobering reading. Humira in ulcerative colitis reviews With the recent approval of Humira (Adalimumab) by the FDA, there is a growing need for ulcerative colitis patient reviews of their experiences … [Read more...] about Humira in Ulcerative Colitis

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Interim pages omitted …
  • Page 58
  • Go to Next Page »

Primary Sidebar

Recent Posts

  • Health, Care and Science in Real Life
  • Request for American Psychiatric Association Assistance
  • Partnerships in Healthcare
  • From Just Say No to Getting to Yes
  • Ground Control to RSV – RSVP

Categories

Footer

Contact

Terms | Privacy

Follow

  • Facebook
  • Twitter
  • YouTube

Search

Copyright © 2025 · Data Based Medicine Global Ltd.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.